Vitamin B3 (as Niacin)
Introduction to Vitamin B3 Biochemistry
Vitamin B3 is a water-soluble vitamin that encompasses three primary vitamers: nicotinic acid (niacin), nicotinamide (niacinamide), and nicotinamide riboside. In physiological systems, these compounds function primarily as precursors to nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+). These pyridine nucleotides are obligate coenzymes for over 400 oxidoreductase enzymes in the human body, mediating critical metabolic pathways including glycolysis, the citric acid cycle (TCA), oxidative phosphorylation, and fatty acid beta-oxidation.
Biosynthetic Pathways of NAD+
The synthesis of NAD+ occurs via three distinct pathways, depending on the precursor utilized:
1. The Preiss-Handler Pathway: Nicotinic acid is converted to nicotinic acid mononucleotide (NaMN) by the enzyme nicotinic acid phosphoribosyltransferase (NAPRT; EC 2.4.2.11). NaMN is then adenylated by nicotinamide mononucleotide adenylyltransferase (NMNAT; EC 2.7.7.1) to form nicotinic acid adenine dinucleotide (NaAD). Finally, NAD synthetase (NADS; EC 6.3.1.5) amidates NaAD to generate NAD+.
2. The Salvage Pathway: Nicotinamide is converted directly to nicotinamide mononucleotide (NMN) by nicotinamide phosphoribosyltransferase (NAMPT; EC 2.4.2.12), the rate-limiting enzyme in this pathway. NMN is subsequently converted to NAD+ by NMNAT.
3. De Novo Biosynthesis: NAD+ can be synthesized from the essential amino acid tryptophan through the kynurenine pathway, though this is highly inefficient, requiring approximately 60 mg of tryptophan to produce 1 mg of niacin equivalent (NE).
Lipid Metabolism and the HCAR2 Receptor
The pharmacological effects of nicotinic acid on lipid profiles—specifically the lowering of low-density lipoprotein (LDL) and the elevation of high-density lipoprotein (HDL)—are mediated through mechanisms distinct from its role as a vitamin. Nicotinic acid is a high-affinity agonist for the hydroxycarboxylic acid receptor 2 (HCAR2), also known as GPR109A.
HCAR2 is a Gi/Go-protein coupled receptor highly expressed on the surface of white adipocytes and immune cells (such as macrophages and Langerhans cells). When nicotinic acid binds to HCAR2 on adipocytes, it induces the dissociation of the Gi alpha subunit, which subsequently inhibits adenylyl cyclase (EC 4.6.1.1). This inhibition leads to a decrease in intracellular cyclic AMP (cAMP) levels, thereby reducing the activity of protein kinase A (PKA).
Decreased PKA activity results in the dephosphorylation and subsequent inactivation of hormone-sensitive lipase (HSL; EC 3.1.1.79). The inactivation of HSL halts lipolysis, drastically reducing the hydrolysis of triglycerides and the subsequent release of non-esterified free fatty acids (NEFAs) into the systemic circulation.
With a reduced influx of NEFAs to the liver, hepatic synthesis of triglycerides is curtailed. This directly limits the assembly and secretion of very-low-density lipoproteins (VLDL). Because VLDL is the metabolic precursor to LDL, a reduction in VLDL secretion inherently lowers circulating LDL levels. Furthermore, nicotinic acid decreases the fractional catabolic rate of apolipoprotein A-I (ApoA-I), the primary structural protein of HDL, thereby increasing circulating HDL levels and promoting reverse cholesterol transport.
The Mechanism of the Niacin Flush
The most prominent acute side effect of nicotinic acid is cutaneous vasodilation, commonly known as the 'niacin flush'. This phenomenon is also mediated by the HCAR2 receptor, but via a different cellular target. Nicotinic acid binds to HCAR2 expressed on epidermal Langerhans cells. This binding triggers an intracellular signaling cascade that activates phospholipase A2 (PLA2), which cleaves arachidonic acid from membrane phospholipids.
Arachidonic acid is rapidly metabolized by cyclooxygenase-1 (COX-1; EC 1.14.99.1) into prostaglandin H2 (PGH2). PGH2 is then converted into prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2) by their respective synthases. These prostaglandins are released into the extracellular space and bind to DP1, EP2, and EP4 receptors on the smooth muscle cells of dermal blood vessels. The activation of these receptors causes profound vasodilation, resulting in the characteristic erythema, warmth, and tingling sensation of the flush.
Pharmacokinetics and Hepatotoxicity
Nicotinic acid is rapidly and extensively absorbed from the gastrointestinal tract, with a Tmax (time to peak plasma concentration) of approximately 45 minutes for immediate-release formulations. It undergoes extensive first-pass hepatic metabolism via two primary pathways:
1. Conjugation Pathway: Nicotinic acid is conjugated with glycine to form nicotinuric acid (NUA), which is excreted in the urine. This pathway is a high-affinity, low-capacity system. It is primarily responsible for the flushing side effect.
2. Amidation Pathway: Nicotinic acid is amidated to nicotinamide, which is then methylated by nicotinamide N-methyltransferase (NNMT; EC 2.1.1.1) to form N-methylnicotinamide (MNA) and other pyridone metabolites. This is a low-affinity, high-capacity system.
Extended-release formulations of niacin are designed to bypass the conjugation pathway and heavily utilize the amidation pathway to avoid flushing. However, excessive reliance on the amidation pathway at high doses (≥1,500 mg) can deplete hepatic methyl donors (like S-adenosylmethionine, SAMe) and lead to the accumulation of hepatotoxic metabolites, explaining the increased risk of liver toxicity associated with high-dose, extended-release niacin.
Glycemic Control Impairment
High doses of nicotinic acid (≥1,500 mg) are associated with a worsening of glycemic control. The exact mechanism is multifactorial. While nicotinic acid initially suppresses free fatty acid release, chronic administration can lead to a 'rebound' effect where free fatty acid levels rise during the fasting state, inducing skeletal muscle insulin resistance. Additionally, HCAR2 activation may directly interfere with insulin signaling pathways or reduce insulin secretion from pancreatic beta cells, leading to the small but significant detriments in blood glucose levels observed in clinical trials.
What is Vitamin B3 (Niacin)? +
What is the difference between niacin and nicotinamide? +
How much Vitamin B3 should I take daily? +
What is the niacin flush? +
Is the niacin flush dangerous? +
How can I prevent the niacin flush? +
Does niacin lower cholesterol? +
Does niacin prevent heart attacks? +
Can niacin cause liver damage? +
Does niacin affect blood sugar? +
What is 'no-flush' niacin? +
Does 'no-flush' niacin lower cholesterol? +
Should I take niacin with food? +
What is the Upper Tolerable Limit (UL) for niacin? +
Can pregnant women take niacin? +
What are the signs of a Vitamin B3 deficiency? +
Can I get enough niacin from food? +
Everything About Vitamin B3 (as Niacin) Article
What It Is Vitamin B3 is an essential water-soluble vitamin required by the body to synthesize NAD+ and NADP+, coenzymes that are fundamental to cellular energy production, metabolism, and DNA repair. In the supplement world, Vitamin B3 is most commonly found in two forms: nicotinic acid (often just called niacin) and nicotinamide (niacinamide). While both forms successfully prevent Vitamin B3 deficiency, they behave very differently in the body at high doses.
The Science: The Cholesterol Paradox For decades, nicotinic acid was a frontline treatment for dyslipidemia (abnormal cholesterol levels). When taken in large doses (500mg to 2,000mg), nicotinic acid binds to a specific receptor in fat cells called HCAR2. This binding stops the breakdown of fats, reducing the amount of free fatty acids traveling to the liver. As a result, the liver produces less VLDL and LDL ('bad') cholesterol, while simultaneously increasing HDL ('good') cholesterol.
However, modern clinical research has revealed a massive paradox. Based on data from over 100,000 participants across multiple meta-analyses, niacin does not reduce the risk of dying from cardiovascular disease or all-cause mortality. It makes your bloodwork look better on paper, but it fails to translate into actual life-saving outcomes. Because of this, its use as a standalone cholesterol treatment has become highly controversial in modern medicine.
What The Research Says The clinical data on Vitamin B3 is robust and definitive: Lipid Profiles: Grade A and B evidence confirms that nicotinic acid effectively lowers LDL and raises HDL. Mortality: Grade D evidence (meaning strong evidence of no effect) shows that despite the cholesterol improvements, niacin does not prevent heart attacks or extend lifespan. Blood Sugar: Grade F evidence shows that high doses of niacin actually cause a small but significant detriment to blood glucose levels and glycemic control.
The Niacin Flush If you take more than 35-50mg of nicotinic acid, you will likely experience the 'niacin flush'. This is a sudden, intense warming, reddening, and tingling sensation on the skin, usually starting at the face and moving down the chest. It occurs because nicotinic acid triggers the release of prostaglandins, which cause blood vessels near the skin to dilate rapidly. While uncomfortable and sometimes alarming to first-time users, the flush is generally harmless and subsides within 1 to 2 hours.
Forms Compared: The 'No-Flush' Myth Supplement manufacturers know consumers hate the flush, so they created 'no-flush' niacin using forms like nicotinamide or inositol hexanicotinate.
Here is the critical truth: While these forms will not cause flushing, they also do not lower cholesterol. The chemical structure required to bind to the lipid-regulating receptors in the body is specific to nicotinic acid. If you are taking a 'no-flush' niacin supplement to improve your lipid panel, you are wasting your money.
Dosing Guide For General Health (Preventing Deficiency): 14mg to 16mg daily (the standard RDA). For Cholesterol Management: 500mg to 1,500mg daily of nicotinic acid. Upper Tolerable Limit (UL): 35mg daily. This limit is set specifically to avoid the flushing side effect, not because higher doses are immediately toxic.
When & How To Take It If you are taking high-dose nicotinic acid, always take it with food. Consuming it alongside a meal slows down its absorption into the bloodstream, which significantly blunts the severity of the flush.
Who Should NOT Take It Diabetics: Doses of 1,500mg or higher can worsen insulin resistance and elevate blood sugar. Those with Liver Issues: High doses, especially of extended-release forms, are processed by the liver and can cause hepatotoxicity. Pregnant Women: While the RDA for pregnancy is 18mg, high-dose niacin should be avoided unless prescribed by a doctor.
The Bottom Line Vitamin B3 is essential for life, and getting your daily 15mg is non-negotiable for cellular energy. However, using mega-doses of niacin to manipulate cholesterol is an outdated practice. While it will successfully change your lipid numbers, the highest quality evidence shows it won't actually protect your heart, and it comes with uncomfortable side effects like flushing and potential risks to your blood sugar and liver.